Helen Collins's most recent trade in Enliven Therapeutics Inc was a trade of 45,000 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on Feb. 17, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 17 Feb 2026 | 45,000 | 70,000 | - | 2.5 | 111,600 | Common Stock |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 17 Feb 2026 | 45,000 | 221,268 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 26.17 per share. | 17 Feb 2026 | 45,000 | 25,000 | - | 26.2 | 1,177,862 | Common Stock |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 150,000 | 150,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2026 | 25,000 | 25,000 | - | 0 | Common Stock | |
| IO Biotech Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 35,144 | 35,144 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2025 | 28,500 | 28,500 | - | - | Option to purchase common stock | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 171,000 | 171,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 18 Oct 2024 | 816 | 816 | - | 2.5 | 2,024 | Common Stock |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Oct 2024 | 816 | 266,268 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Oct 2024 | 816 | 0 | - | 30.0 | 24,482 | Common Stock |
| IO Biotech Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jun 2024 | 45,642 | 45,642 | - | - | Stock Option (Right to Buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 2.48 per share. | 11 Apr 2024 | 20,000 | 20,000 | - | 2.5 | 49,600 | Common Stock |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2024 | 20,000 | 267,084 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | CHIEF MEDICAL OFFICER | Sale of securities on an exchange or to another person at price $ 25.07 per share. | 11 Apr 2024 | 20,000 | 0 | - | 25.1 | 501,478 | Common Stock |
| Enliven Therapeutics Inc | Collins Helen | CHIEF MEDICAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 185,000 | 185,000 | - | - | Stock Option (right to buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 26,000 | 26,000 | - | - | Option to purchase common stock | |
| Enliven Therapeutics Inc | Helen Collins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 206,000 | 206,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Helen Collins | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 287,084 | 287,084 | - | - | Employee Stock Option (right to buy) | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Jun 2022 | 23,000 | 23,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 46,000 | 46,000 | - | - | Option to purchase common stock | |
| Kura Oncology Inc | Helen Collins | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jul 2021 | 19,166 | 19,166 | - | - | Option to purchase common stock |